74786-02-0

Usage

Uses

Used in Organic Synthesis:
[[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane is used as a reagent in organic synthesis, particularly for cross-coupling reactions. Its presence facilitates the formation of new carbon-carbon or carbon-heteroatom bonds, which are essential in constructing complex organic molecules.
Used in Advanced Materials Production:
In the field of materials science, [[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane serves as a building block for the development of advanced materials. Its incorporation into material structures can enhance properties such as stability, reactivity, or specific functional characteristics, depending on the application.
Used in Pharmaceutical Industry:
[[1-(tert-butoxy)ethenyl]oxy](tert-butyl)dimethylsilane is utilized as a key intermediate in the synthesis of pharmaceuticals. Its unique structure allows for the creation of new drug candidates with potential therapeutic effects, contributing to the discovery and development of novel medications.
These applications highlight the compound's significance in chemical research and development, showcasing its adaptability and importance across different industries.

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 102340-98-7 (4SR,5SR)-2,2-dimethyl-4-hydroxy-5-(benzyloxy)heptan-3-one 
• 102285-99-4 tert butyl (3SR,4SR)-3-hydroxy-4-(benzyloxy)pentanoate 
• 102285-93-8 tert butyl (3RS,4SR)-3-hydroxy-4-(benzyloxy)pentanoate 
• 121614-12-8 tert-butyl (4S)-3--4,5-(isopropylidenedioxy)pentanoate 
• 113778-38-4 (3S^*,5S^*)-3,5-dihydroxy-6-methylheptanoic acid δ-lactone 
• 84850-33-9 (3S,4R)-3-Hydroxy-4-phenyl-pentanoic acid tert-butyl ester 
• 84850-33-9 (3R,4R)-3-Hydroxy-4-phenyl-pentanoic acid tert-butyl ester 
• 111524-19-7 tert-butyl (4S,5S)-3--4,5-(isopropylidenedioxy)hexanoate 
• 99686-73-4 (R)-6,6-Dimethyl-5-oxo-3-((S)-1-phenyl-ethyl)-heptanoic acid 
• 99686-73-4 (S)-6,6-Dimethyl-5-oxo-3-((S)-1-phenyl-ethyl)-heptanoic acid 
• 111554-02-0 tert-butyl (3S,4S,5S)-3--4,5-(isopropylidenedioxy)hexanoate 
• 111524-22-2 tert-butyl (4S,5S)-3--4,5-(isopropylidenedioxy)hexanoate 
• 84850-39-5 (3S,4R)-4-Cyclohexyl-3-hydroxy-pentanoic acid tert-butyl ester 
• 84850-39-5 (3R,4R)-4-Cyclohexyl-3-hydroxy-pentanoic acid tert-butyl ester 

Relevant academic research and scientific papers

Diastereoselectivity in the Lewis Acid Mediated Aldol Reaction of Chiral α, β-Epoxyaldehydes with a Ketene Silyl Acetal

The Lewis acid mediated aldol reaction of chiral α, β-cis and trans epoxyaldehydes 1 and 2 with tert-butyl ketene silyl acetal proceeds mainly with anti diastereofacial preference. The best results were obtained for cis epoxyaldehyde 1 in the presence of catalytic amounts of BiCl3 · 1.5 eq. ZnI2 (anti:syn ～ 13:1), whereas the poorest stereoselectivity was observed when an excess of LiClO4 was used (anti:syn ～ 1:1). The more stable epoxyaldehyde conformers were determined and the diastereofacial preference was found to be in agreement with a nucleophilic attack on the energetically more favoured conformers.

Novel nonadride, heptadride and maleic acid metabolites from the byssochlamic acid producer Byssochlamys fulva IMI 40021-an insight into the biosynthesis of maleidrides

The filamentous fungus Byssochlamys fulva strain IMI 40021 produces (+)-byssochlamic acid 1, its novel dihydroanalogue 2 and four related secondary metabolites. Agnestadrides A, 17 and B, 18 constitute a novel class of seven-membered ring, maleic anhydride-containing (hence termed heptadride) natural products. The putative maleic anhydride precursor 5 for both nonadride and heptadride biosynthesis was isolated as a fermentation product for the first time and its structure confirmed by synthesis. Acid 5 undergoes facile decarboxylation to anhydride 6. The generic term maleidrides is proposed to encompass biosynthetically-related compounds containing maleic anhydride moieties fused to an alicyclic ring, varying in size and substituents.

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I): where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: ■ a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ■ -(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ■ an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ■ a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.